Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy.

about

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy.

Item

http://www.wikidata.org/entity/Q49507285

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Multiple epidermotropic melano ...... RAF and MEK inhibitor therapy.

@en

Multiple epidermotropic melano ...... RAF and MEK inhibitor therapy.

@nl

type

Item

label

Multiple epidermotropic melano ...... RAF and MEK inhibitor therapy.

@en

Multiple epidermotropic melano ...... RAF and MEK inhibitor therapy.

@nl

prefLabel

Multiple epidermotropic melano ...... RAF and MEK inhibitor therapy.

@en

Multiple epidermotropic melano ...... RAF and MEK inhibitor therapy.

@nl

P1476

Multiple epidermotropic melano ...... BRAF and MEK inhibitor therapy

@en

P2093

Azadeh Orouji

http://www.w3.org/2001/XMLSchema#string

Lionel Larribère

http://www.w3.org/2001/XMLSchema#string

Nolwenn Maurier

http://www.w3.org/2001/XMLSchema#string

Raphael Reinhard

http://www.w3.org/2001/XMLSchema#string

P2860

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

CO2 laser treatment for regional cutaneous malignant melanoma metastases.

New therapeutic options for advanced non-resectable malignant melanoma.

Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors.

Cutaneous metastases of malignant melanoma: a clinicopathologic study of 192 cases with emphasis on the morphologic spectrum.

P304

129-131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1016/J.JDCR.2017.09.007

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jochen Utikal

Christoffer Gebhardt

P577

2018-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29387762

http://www.w3.org/2001/XMLSchema#string

P932

5789521

http://www.w3.org/2001/XMLSchema#string